Cogent Biosciences reports Q4/FY2025 results; advances bezuclastinib NDAs in SM and GIST

Cogent Biosciences, Inc.

2025-FY EPS reported -$2.16

SUMMIT NDA for bezuclastinib in NonAdvSM submitted Dec 2025; APEX NDA for AdvSM on track for 1H 2026.
PEAK NDA for bezuclastinib in 2L GIST initiated under RTOR and BTD; completion expected April 2026.
Cash, equivalents and marketable securities $900.8M as of Dec 31, 2025, sufficient into 2028.
Net loss $102.5M in Q4 2025, $328.9M full year, vs $67.9M and $255.9M in prior year periods.
Inducement grants: options to purchase 59,300 shares and 47,000 RSUs to 12 new employees.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.